ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2014
Comparison of two commercially available ELISAs for circulating sclerostin.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.AIDS research and human retroviruses · 2015Trial
- Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus.Journal of clinical & translational endocrinology · 2025Article
- The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM.Clinica chimica acta; international journal of clinical chemistry · 2021Article
- Meta-analysis of the association between sclerostin level and adverse clinical outcomes in patients undergoing maintenance haemodialysis.Therapeutic advances in chronic disease · 2021Article
- Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus.Bone reports · 2020Article
- Article
- The Utility of Biomarkers in Osteoporosis Management.Molecular diagnosis & therapy · 2017Review
- Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.Endocrine · 2017Review
- Bone resorption following weight loss surgery is associated with treatment procedure and changes in secreted Wnt antagonists.Endocrine · 2016Article
- How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits.Calcified tissue international · 2016Article
- Sclerostin and CKD-MBD.Current osteoporosis reports · 2015Review
- Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?International urology and nephrology · 2015Article
- Serum sclerostin is an independent predictor of mortality in hemodialysis patients.BMC nephrology · 2014Article
- Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients.Discoveries (Craiova, Romania)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
unlabelledThis study investigates the performance and correlation of sclerostin measurements by two commercially available sclerostin ELISAs from TECOmedical and Biomedica. We found that the correlation between the results of two sclerostin assays is strong.
introductionCirculating sclerostin levels may provide insight into the pathophysiology of metabolic bone diseases such as osteoporosis. However, recent studies suggest that commercially available assays give different results. We compare the analytical performance of the two most used commercially available sclerostin ELISAs from TECOmedical and Biomedica.
methodsSclerostin levels were assessed in 20 paired serum, EDTA, and heparin plasma convenience samples from hospitalized patients. In addition, sclerostin was measured in serum samples from 34 patients with metabolic bone diseases and from 10 patients with chronic kidney disease (CKD). Samples from three healthy donors were used to determine stability and intra- and inter- assay precision.
resultsThe average serum sclerostin concentration of all patients (n = 64) was 0.713 ± 0.58 ng/mL with the Biomedica assay and 0.734 ± 0.43 ng/mL with the TECO assay (p < 0.05). The results correlated strongly (r = 0.9; p < 0.0001), with Passing-Bablok regression showing a linear relationship but with a slight systematic and proportional difference between both assays. Sclerostin levels were about 30% higher in plasma than in serum for both assays, while no significant difference was seen between EDTA and heparin plasma. Intra- and inter- precision were <10% for TECO and <20% for Biomedica. Samples were stable for up to three freeze-thaw cycles with both assays.
conclusionsThe two commercially available ELISAs for measuring circulating levels of sclerostin are comparable. However, given the small but statistically significant systematic and proportional differences between both assays, results and reference ranges will be assay-specific. Results will also be specific to serum or plasma.
Indexed as
Identifiers
24562839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.